3-amino-N-[(1R)-5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]-2-adamantyl]propanamide
C25H31FN4O2 — CID 122499123
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-amino-N-[(1R)-5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]-2-adamantyl]propanamide
3-amino-N-[(1R)-5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]-2-adamantyl]propanamide (PubChem CID 122499123) has the molecular formula C25H31FN4O2 and a molecular weight of 438.55 g/mol. Its IUPAC name is 3-amino-N-[(1R)-5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]-2-adamantyl]propanamide.
Molecular Properties
| Compound Name | 3-amino-N-[(1R)-5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]-2-adamantyl]propanamide |
|---|---|
| PubChem CID | 122499123 |
| Molecular Formula | C25H31FN4O2 |
| Molecular Weight | 438.55 g/mol |
| Exact Mass | 438.24 |
| IUPAC Name | 3-amino-N-[(1R)-5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]-2-adamantyl]propanamide |
| SMILES | NCCC(=O)NC1C2CC3C[C@@H]1CC(C(O)CC1c4c(F)cccc4-c4cncn41)(C3)C2 |
| InChI | InChI=1S/C25H31FN4O2/c26-18-3-1-2-17-20-12-28-13-30(20)19(23(17)18)8-21(31)25-9-14-6-15(10-25)24(16(7-14)11-25)29-22(32)4-5-27/h1-3,12-16,19,21,24,31H,4-11,27H2,(H,29,32)/t14?,15-,16?,19?,21?,24?,25?/m1/s1 |
| InChIKey | NOYWFOBWNZKGMF-MSYNKTHXSA-N |
| XLogP | 3.00 |
| TPSA | 93.17 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 438.55 |
| LogP ≤ 5 | 3.00 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122499123 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.